Tiziana Life Sciences Ltd
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsTiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market under the ticker TLSA, incorporated in Bermuda and operating through subsidiaries in the U.K. and Italy.
What they do
Tiziana is a pharmaceutical preparations company whose wholly owned subsidiaries are Tiziana Life Sciences Ltd (formerly Tiziana Life Sciences plc), Tiziana Therapeutics Inc., Tiziana Pharma Limited and Longevia Genomics S.r.l. The company is issuing an annual report on Form 20-F for the fiscal year ended December 31, 2025, and its securities are registered under Section 12(b) of the Exchange Act on the Nasdaq Capital Market. Its financial statements are prepared under IFRS as issued by the IASB, presented in U.S. dollars. No product-level operations beyond the subsidiary structure are disclosed in the excerpt provided.
Revenue drivers
- Not disclosed in excerpt — The provided filing excerpt does not identify any product lines, customers, or revenue-generating segments.
Recent performance
The source excerpt does not include financial results for the year ended December 31, 2025. It states that audited consolidated financial statements were prepared under IFRS as issued by the IASB for 2025 and 2024, and that none of the statements were prepared under U.S. GAAP. All U.S. dollar figures in the report are translated from Pounds Sterling at 1.00 to $1.3387, the December 31, 2025 closing spot rate. Because no income statement, balance sheet, or cash flow figures are included in the excerpt, revenue, costs, and net results cannot be stated.
Strategy
No strategy, pipeline, or investment priorities are described in the excerpt. The only structural information is the company's subsidiary list: Tiziana Life Sciences Ltd, Tiziana Therapeutics Inc., Tiziana Pharma Limited and Longevia Genomics S.r.l. The filing is an annual report for the fiscal year ended December 31, 2025, dated 2026-05-01. No forward-looking plans, partnerships, or capital allocation statements are present in the source text.
Risks
- Clinical-stage biopharmaceutical risk — As a company in the Pharmaceutical Preparations industry with no disclosed revenue-generating segment, Tiziana would depend on successful development and commercialization of its candidates, but the excerpt does not identify any pipeline or product.
- Foreign private issuer / IFRS reporting — Financial statements are prepared under IFRS as issued by the IASB rather than U.S. GAAP, so readers should note accounting differences when comparing against U.S. GAAP filers.
- Controlled company / governance structure — The excerpt lists a 2021 8-K noting a change in control, director or officer change, and amended charter or bylaws, indicating past governance and control changes relevant to shareholder rights.
- Currency and translation risk — U.S. dollar convenience translations were made at a single spot rate of 1.00 to $1.3387, which the filing states is not necessarily indicative of amounts that could actually have been purchased at the dates indicated.
Outlook
The excerpt provided does not contain any management outlook, guidance, or forward-looking operational milestones. It only confirms the report is an annual report under Section 13 or 15(d) of the Exchange Act for the fiscal year ended December 31, 2025. No near-term priorities or expected timelines are stated in the source text.